The OXPHOSight™ Fumarate Assay Kit measures fumarate accumulation to investigate hypoxia response pathways and the efficacy of metabolic inhibitors in oncology. Precise metabolite quantification aids in oncometabolite research, supporting the investigation of hypoxia-inducible factor (HIF) stabilization. This tool is essential for elucidating the metabolic adaptations of cancer cells and identifying vulnerabilities for therapeutic intervention.
Features
Precise metabolite quantification aids in oncometabolite research; Supports investigation of hypoxia-inducible factor (HIF) pathways in oncology.
Process Relevance
Oncology Target Validation (Oncometabolites)
Application Stage
Target Validation
Applications
Critical for studying mitochondrial diseases.
Qualified With
Internal performance validation using reference standards under defined assay conditions.
Detection Method
Absorbance at 565 nm
Sample Type
Food, beverage and other biological samples (serum, citrate-plasma, urine, cell lysate, culture medium)
Research Areas
Oncology (Oncometabolites); Metabolic Disease
Size
100 tests
Data Output Type
Quantitative (Concentration)
Assay Time
Results in 30 min
LOD
5 µM
Species
All Species
Storage
Store at −20 °C upon receipt to maintain reagent stability. Follow recommended handling procedures to ensure consistent assay performance.
Storage Comment
Avoid repeated freeze-thaw cycles. During use, minimize the time components are exposed to room temperature and return them promptly to −20 °C storage after handling. Do not store at elevated temperatures for extended periods.
Expiry Date
6 months under recommended storage conditions to ensure optimal performance.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Shipped on ice under temperature-controlled conditions.
Background
Fumarate is an intermediate in the Krebs cycle and the urea cycle. Recently identified as an oncometabolite its accumulation in cells with fumarate hydratase mutations can drive tumorigenesis by stabilizing hypoxia-inducible factors.